Still trying to pick the best asparaginase preparation
Mené sur 463 patients pédiatriques atteints d'une leucémie lymphoblastique aiguë, cet essai multicentrique randomisé de phase III compare l'efficacité, du point de vue de la survie sans maladie, et les toxicités associées à une administration intraveineuse de L-asparaginase pégylée et à une administration intramusculaire de L-asparaginase
Since the early 1970s, the Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukaemia (ALL) Consortium has undertaken many successful clinical trials in childhood acute lymphoblastic leukaemia, which are mainly characterised by an early and prolonged intensification therapy with high-dose asparaginase, a drug that is regarded as a mainstay of treatment for this disease.1In The Lancet Oncology, Andrew Place and colleagues report the results of the DFCI ALL Consortium protocol 05-001,2 a phase 3 randomised open-label trial that compared, after induction therapy, the use of 15 biweekly doses of intravenous PEG-asparaginase with 30 weekly doses of intramuscular native Escherichia coli (E coli) l-asparaginase.
The Lancet Oncology 2015